This compound has shown clinical efficacy on different clinical manifestations of Fabry disease (Germain et al, 2016; Hughes et al, 2017; Lenders et al, 2020) and is now approved for the treatment of patients with amenable GLA gene mutations. Here, GLA is linked to Fabry disease.